Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | CTNNB1 S33F |
Gene Variant Detail | |
Relevant Treatment Approaches | CTNNB1 Inhibitor PDPK1 Inhibitor Tankyrase Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
CTNNB1 S33F | colorectal cancer | predicted - resistant | Tankyrase Inhibitor | G007-LK | Preclinical | Actionable | In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing CTNNB1 S33F (corresponding to S33F in human) in culture (PMID: 31337618). | 31337618 |
CTNNB1 S33F | hepatocellular carcinoma | sensitive | WNTinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, WNTinib inhibited Ezh2 phosphorylation and viability in a patient-derived hepatocellular carcinoma cell line harboring CTNNB1 S33F in 2D and 3D culture (PMID: 37537299). | 37537299 |